Harrow, Inc.HROW
Price (close)
$33.10
Market cap
$1.2B
P/E
—
Revenue (TTM)
$275.6M
Net income
-$37.2M
Dividend yield
—
1-year total return
-28.3%
Net margin
-13.5%
Revenue growth
21.1%
Debt / equity
19.24x
What Harrow, Inc. does.
are a leading provider of ophthalmic disease management solutions in North America, and were founded with a commitment to deliver safe,
effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For over a decade, we
have partnered with U.S. eyecare professionals to develop a comprehensive portfolio of high-quality products used to manage ophthalmic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $48.9M | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Net income | -$3.4M | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| Free cash flow | -$2.0M | $3.3M | -$892,000 | $2.4M | -$23.8M | $43.0M |
More on HROW.
- Harrow, Inc. summary
- Harrow, Inc. financial statements
- Harrow, Inc. key metrics
- Harrow, Inc. health scores and style box
- Harrow, Inc. earnings
- Harrow, Inc. dividends
- Harrow, Inc. valuation
- Harrow, Inc. ownership and insiders
- Harrow, Inc. peers
Figures from Harrow, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.